PMID- 35963931
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230110
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 13
IP  - 10
DP  - 2022 Oct
TI  - Association of Time in Range with Endothelial Injury in Patients with Type 2 
      Diabetes Treated with Exenatide.
PG  - 1755-1767
LID - 10.1007/s13300-022-01310-3 [doi]
AB  - INTRODUCTION: We aimed to investigate whether treatment with exenatide could 
      increase time in range (TIR) and decrease glycemic variability, and to evaluate 
      the association between TIR and endothelial injury in patients with type 2 
      diabetes mellitus (T2DM). METHODS: Two-hundred patients with T2DM treated with 
      exenatide for 16 weeks were included in this study. Seven-point fingerstick blood 
      glucose was used to evaluate derived TIR and glycemic variability. The serum 
      levels of soluble endothelial cell protein C receptor (sEPCR) and von Willebrand 
      factor (vWF) were measured. Ninety-three patients having the data of endothelial 
      injury markers were categorized as derived TIR > 70% or </= 70% after the treatment 
      and the association between TIR and endothelial injury were evaluated. RESULTS: 
      Treatment with exenatide for 16 weeks resulted in a significant reduction in 
      fasting blood glucose, postprandial 2 h blood glucose, and glycated 
      hemoglobin A1c (HbA1c) levels in patients with T2DM. Compared with baseline, 
      derived TIR value was significantly increased [85.7 (57.1, 100.0) % vs. 42.9 
      (14.9, 71.4) %, P < 0.001], and the parameters of glycemic variability were 
      remarkably decreased after the treatment. After the treatment, serum sEPCR level 
      was significantly decreased from baseline in patients with TIR > 70% [74.5 (32.8, 
      122.5) ng/mL vs. 96.9 (48.5, 150.9) ng/mL, P = 0.006] but not in those with 
      TIR </= 70%; serum vWF level was remarkably decreased in patients with TIR > 70% 
      [from 1166.2 (848.1, 1335.5) mIU/mL to 907.4 (674.3, 1335.1) mIU/mL, P = 0.001] 
      while this effect was modest in those with TIR </= 70%. CONCLUSIONS: Treatment with 
      exenatide increases TIR and decreases glycemic variability in patients with T2DM. 
      Moreover, the amelioration of endothelial injury is more pronounced in patients 
      with TIR > 70% after the treatment. TRIAL REGISTRATION: ChiCTR-IPR-15006558 
      (registered, 27 May 2015).
CI  - (c) 2022. The Author(s).
FAU - Le, Yunyi
AU  - Le Y
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China.
FAU - Yang, Kun
AU  - Yang K
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China.
FAU - Yang, Jin
AU  - Yang J
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China.
FAU - Fu, Wei
AU  - Fu W
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China.
FAU - Xiao, Wenhua
AU  - Xiao W
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China.
FAU - Wei, Rui
AU  - Wei R
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China. weirui@bjmu.edu.cn.
FAU - Hong, Tianpei
AU  - Hong T
AUID- ORCID: 0000-0002-5744-5129
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital, 49 
      North Garden Road, Haidian District, Beijing, 100191, China. tpho66@bjmu.edu.cn.
LA  - eng
GR  - 81830022/National Natural Science Foundation of China/
GR  - 82170875/National Natural Science Foundation of China/
GR  - 82070319/National Natural Science Foundation of China/
GR  - 7212127/Natural Science Foundation of Beijing/
GR  - 2018YFC1313900/National Key Research and Development Program of China/
GR  - 2020-3-40914/Capital's Funds for Health Improvement and Research/
PT  - Journal Article
DEP - 20220813
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC9500125
OTO - NOTNLM
OT  - Diabetic vascular complications
OT  - Endothelial injury
OT  - Exenatide
OT  - Glycemic variability
OT  - Time in range
EDAT- 2022/08/14 06:00
MHDA- 2022/08/14 06:01
PMCR- 2022/08/13
CRDT- 2022/08/13 23:20
PHST- 2022/07/01 00:00 [received]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/08/14 06:00 [pubmed]
PHST- 2022/08/14 06:01 [medline]
PHST- 2022/08/13 23:20 [entrez]
PHST- 2022/08/13 00:00 [pmc-release]
AID - 10.1007/s13300-022-01310-3 [pii]
AID - 1310 [pii]
AID - 10.1007/s13300-022-01310-3 [doi]
PST - ppublish
SO  - Diabetes Ther. 2022 Oct;13(10):1755-1767. doi: 10.1007/s13300-022-01310-3. Epub 
      2022 Aug 13.